ANN ARBOR, Mich. — NanoBio Corp. announced Dec. 7 that its recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine elevated immune responses in studies when they were administered via injections instead of through nasal sprays.
NanoBio said these studies are unique because the adjuvant was administered for the first time by subcutaneous and intramuscular injections.
NanoBio says its adjuvanted vaccines administered by injections should share many of the advantages, including antigen-sparing properties, previously demonstrated in studies where the adjuvant was administered intranasally.
“It is encouraging that these strong immune responses were achieved without evidence of significant irritation or inflammation, which could differentiate these IM [intramuscular] vaccines from currently approved IM adjuvants,” said James R. Baker, founder and CEO of NanoBio Corp.
“These new data further demonstrate the broad safety and potential universal applicability of NanoBio’s vaccine adjuvant platform for immunization in a method most appropriate for the particular disease.”
Baker will present data on these studies Dec. 9 at the World Influenza Congress in Brussels, Belgium.
The underlying technology is NanoBio’s NanoStat platform, which employs a nanoemulsion that is created through a proprietary manufacturing process. The nanoemulsion has previously proved to be uniquely capable of permeating the nasal mucosa, where it can load vaccine antigen into immune-presenting cells.
Earlier this year, the U.S. Food and Drug Administration approved the company’s Investigational New Drug application for the phase-1 clinical study of a seasonal influenza vaccine administered via a nasal dropper. The phase-1 study is ongoing.
NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases.